C - Chemistry – Metallurgy – 08 – B
Patent
C - Chemistry, Metallurgy
08
B
C08B 37/10 (2006.01) A61K 31/727 (2006.01) A61P 9/00 (2006.01) C08B 37/00 (2006.01)
Patent
CA 2293595
The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly useful for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus- related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.
L'invention concerne des compositions et des méthodes permettant de traiter les maladies cardio-vasculaires. Plus particulièrement, elle permet de modifier la formation du thrombus grâce à l'administration d'un agent qui, entre autres, est capable de: (1) inactiver la thrombine en phase fluide et la thrombine liée soit à la fibrine contenue dans un caillot, soit à une autre surface, en catalysant l'antithrombine; et (2) inhiber la production de thrombine en catalysant l'inactivation du facteur Xa par l'antithrombine III (AT III). Les compositions et les méthodes de la présente invention sont particulièrement utiles pour prévenir les thromboses dans le circuit d'un appareil de circulation extra-corporelle et chez les patients dialysés, ainsi que pour traiter les patients souffrant de ou susceptibles de souffrir de troubles cardio-vasculaires liés à un thrombus, tels qu'angor instable, infarctus du myocarde, accident vasculaire cérébral (attaque), embolie pulmonaire, thrombose des veines profondes, thrombose artérielle, etc.
Hirsh Jack
Weitz Jeffrey
Hamilton Civic Hospitals Research Development Inc.
Mccarthy Tetrault Llp
LandOfFree
Modified low molecular weight heparin that inhibits clot... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified low molecular weight heparin that inhibits clot..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified low molecular weight heparin that inhibits clot... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1400396